Boehringer Ingelheim announces the start of the THULITE Phase II clinical study. It will investigate the efficacy, safety and tolerability of BI 1815368 as a potential oral treatment to improve vision ...

A 69-year-old woman was referred to the retina service for abnormal posterior segment findings.The patient’s medical history ...

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...

Age-related macular degeneration (AMD), classified into dry and wet types, poses a significant threat to the vision of the ...

BI 1815368, a potential oral treatment to improve vision in patients with diabetic macular edema, is being investigated in a ...

Canadian study reveals diabetic patients taking GLP-1 medications face twice the risk of eye problems, with longer exposure increasing danger of macular degeneration.

Macular degeneration is a condition that affects the retina, which is neural tissue that lines the back of the eye, like wallpaper in a room. There is an important area in the retina called the ...

The treatment of diabetic macular oedema (DMO) likely involves a series of treatment episodes separated by gaps during which ...

Alcon to Acquire LumiThera and its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD) ...

Age-Related Macular Degeneration Market Epidemiology Report 2025-2035: Drugs Pipeline, Therapies, and Forecast The report provides a detail ...

A large, prospective study implicates high levels of interleukin 6 with severity of diabetic retinopathy and shows it may be ...

Older people with diabetes who do not keep blood sugar levels low are three times more likely to develop eye disease compared ...